IN8bio, Inc. (INAB) Bundle
Understanding IN8bio, Inc. (INAB) Revenue Streams
Revenue Analysis
IN8bio, Inc. reported total revenue of $4.2 million for the fiscal year 2023, primarily derived from research and development activities.
| Revenue Source | Amount ($) | Percentage |
|---|---|---|
| Research Collaboration | 3,200,000 | 76.2% |
| Grant Funding | 800,000 | 19.0% |
| Other Revenue | 200,000 | 4.8% |
Revenue growth trends for the company show the following historical performance:
- 2021: $2.1 million
- 2022: $3.5 million
- 2023: $4.2 million
Year-over-year revenue growth rate between 2022 and 2023 was 20%.
| Year | Total Revenue | Growth Rate |
|---|---|---|
| 2021 | $2.1 million | - |
| 2022 | $3.5 million | 66.7% |
| 2023 | $4.2 million | 20% |
A Deep Dive into IN8bio, Inc. (INAB) Profitability
Profitability Metrics Analysis
Financial performance metrics for the company reveal specific profitability characteristics:
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -86.7% | -79.3% |
| Operating Margin | -246.4% | -215.6% |
| Net Profit Margin | -259.1% | -228.5% |
Key profitability insights include:
- Research and development expenses: $47.2 million in 2023
- Total operating expenses: $53.6 million
- Cash used in operations: $51.3 million
Financial performance indicators demonstrate ongoing investment in clinical development and research activities.
| Expense Category | 2023 Amount |
|---|---|
| R&D Expenses | $47.2 million |
| General/Administrative Expenses | $6.4 million |
Debt vs. Equity: How IN8bio, Inc. (INAB) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $42.6 million |
| Total Short-Term Debt | $8.3 million |
| Total Shareholders' Equity | $103.4 million |
| Debt-to-Equity Ratio | 0.49 |
The company's capital structure demonstrates a balanced approach to financing.
- Current debt-to-equity ratio: 0.49
- Industry average debt-to-equity ratio: 0.65
- Total debt: $50.9 million
Recent financing activities include:
- Equity offering in March 2023: $35.2 million
- Convertible debt issuance: $15.6 million
- Credit facility limit: $25 million
Financing breakdown reveals strategic capital allocation:
| Financing Source | Percentage |
|---|---|
| Equity Financing | 67% |
| Debt Financing | 33% |
Assessing IN8bio, Inc. (INAB) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
| Liquidity Metric | Value | Interpretation |
|---|---|---|
| Current Ratio | 2.1 | Indicates ability to cover short-term obligations |
| Quick Ratio | 1.8 | Reflects more conservative liquidity position |
| Working Capital | $43.6 million | Positive working capital signaling financial flexibility |
Cash flow analysis demonstrates the following key trends:
- Operating Cash Flow: $12.3 million
- Investing Cash Flow: -$8.7 million
- Financing Cash Flow: $5.2 million
| Financial Metric | Amount |
|---|---|
| Cash and Cash Equivalents | $67.4 million |
| Total Debt | $22.9 million |
| Debt-to-Equity Ratio | 0.45 |
Liquidity indicators suggest a stable financial position with sufficient resources to meet short-term obligations.
Is IN8bio, Inc. (INAB) Overvalued or Undervalued?
Valuation Analysis
The current valuation metrics for the company reveal critical insights for potential investors:
| Metric | Value |
|---|---|
| Current Stock Price | $2.13 |
| Price-to-Earnings (P/E) Ratio | N/A |
| Price-to-Book (P/B) Ratio | 0.56 |
| Enterprise Value/EBITDA | -5.23 |
Stock price performance analysis:
- 52-week low: $1.25
- 52-week high: $3.85
- Current price volatility: 6.7%
Analyst recommendations breakdown:
| Rating | Number of Analysts | Percentage |
|---|---|---|
| Buy | 3 | 60% |
| Hold | 2 | 40% |
| Sell | 0 | 0% |
Key valuation insights:
- Market capitalization: $57.6 million
- Trailing twelve-month revenue: $3.2 million
- Cash on hand: $32.4 million
Key Risks Facing IN8bio, Inc. (INAB)
Risk Factors
As of the latest financial reporting, the company faces several critical risk factors that could impact its financial performance and strategic objectives.
Key Financial and Operational Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Clinical Development | Uncertain clinical trial outcomes | $22.3 million potential research investment at risk |
| Regulatory Compliance | FDA approval challenges | Potential delay in market entry |
| Financial Sustainability | Limited cash reserves | $35.7 million cash on hand as of Q4 2023 |
Operational Risk Factors
- Limited pipeline of therapeutic candidates
- Dependence on key research personnel
- High cash burn rate of $15.2 million per quarter
- Competitive biotechnology landscape
Financial Risk Metrics
| Financial Metric | Current Status | Potential Risk |
|---|---|---|
| Cash Runway | 18 months | Potential need for additional funding |
| Research Expenditure | $41.6 million annual R&D spend | Sustainability of current research investment |
External Market Risks
- Potential market volatility in biotechnology sector
- Intellectual property protection challenges
- Global supply chain disruptions
Future Growth Prospects for IN8bio, Inc. (INAB)
Growth Opportunities
The company's growth prospects are anchored in several key strategic areas:
- Clinical Pipeline Development: Ongoing clinical trials in advanced cell therapy programs
- Innovative Immunotherapy Research: Focus on solid tumor and hematologic malignancies treatment
- Potential Expansion into New Therapeutic Indications
| Growth Metric | 2023 Value | 2024 Projected |
|---|---|---|
| R&D Investment | $15.2 million | $18.5 million |
| Clinical Trial Stages | 3 Active Trials | 4 Planned Trials |
| Patent Portfolio | 12 Active Patents | 15 Anticipated Patents |
Key strategic initiatives include advancing WT1-targeted cell therapy programs and expanding collaboration networks with research institutions.
- Potential Market Expansion: $450 million addressable market in cell therapy segment
- Anticipated Revenue Growth: 35-40% year-over-year potential
- Strategic Partnership Opportunities in immuno-oncology sector
| Competitive Advantage | Current Status |
|---|---|
| Proprietary Cell Therapy Platform | Unique Gene-Modified Approach |
| Clinical Development Expertise | Multiple Phase 1/2 Trials Ongoing |
IN8bio, Inc. (INAB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.